CANCERJuly 2012Advanced melanoma selumetinib as monotherapy versus temozolomide in patients with phase II, open-label, randomized trial of the MEK1/2 inhibitor
CANCERJuly 2012RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors